Massachusetts General Hospital
The goal of this clinical trial is to evaluate whether disclosure of a polygenic risk score for coronary artery disease (CAD PRS) influences cardiovascular health and risk factor modification over one year among adults aged 30-75 years in the Mass General Brigham primary care network who are not currently taking LDL cholesterol-lowering medications.
The PROACT 3 clinical trial is designed to evaluate whether disclosure of a polygenic risk score for CAD PRS influences cardiovascular health and risk factor modification over one year. This is a single-center, randomized clinical trial conducted within the Mass General Brigham primary care network. Adults aged 30-75 years without cardiovascular disease and not currently taking LDL cholesterol-lowering medications will be identified through electronic health record queries. A total of 500 participants will be enrolled. All participants will undergo CAD PRS testing. Participants will then be…
Inclusion Criteria: * Current age 30-75 years * Established primary care at Mass General Brigham with at least one visit in the last 2 years Exclusion Criteria: \- Currently taking LDL cholesterol- lowering medications, including statins
Participants receive their CAD PRS results as soon as they are available after genotyping.
Participants receive their CAD PRS results after completion of the 12 month follow up period.
Arctuva estimate
Verify or correct the compensation shown for this listing.